The rise of copyright’s blockbuster initially fueled a boom for major pharmaceutical companies, however recent shifts present a complicated outlook for those considering a stake. Lower-cost alternatives are eating into earnings, and ongoing patent challenges add additional complexity to the landscape. While specific companies might still gain fro